Predictive methylation signature for gemcitabine sensitivity in pancreatic ductal adenocarcinoma: A pathway to personalized treatment.

被引：0
作者：
Sherpally, Deepak
Jeepalyam, Sravan
Puram, Harshitha
Manne, Ashish
机构：
[1] Metropolitan Hosp Ctr, New York, NY USA
[2] Stormont Vail Hlth, Topeka, KS USA
[3] Univ Cincinnati, Cincinnati, OH USA
[4] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.768
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：768 / 768
页数：1
相关论文
共 50 条
[21]   Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine [J].
Lee Cheng Phua ;
Shixu Goh ;
David Wai Meng Tai ;
Wei Qiang Leow ;
Syed Muhammad Fahmy Alkaff ;
Chung Yip Chan ;
Juinn Huar Kam ;
Tony Kiat Hon Lim ;
Eric Chun Yong Chan .
Cancer Chemotherapy and Pharmacology, 2018, 81 :277-289
[22]   Methylation of CALCA and CALCB in Pancreatic Ductal Adenocarcinoma [J].
Gao, Feng ;
Liu, Guozhong ;
Wang, Jingwen ;
Huang, Shirong ;
Ding, Fadian ;
Lian, Wei ;
Lv, Xiaoting ;
Guo, Yujia ;
Fan, Xiangqun ;
Zhang, Sheng ;
Liu, Qicai .
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2021, 2021
[23]   Thermosensitive Liposomes for Gemcitabine Delivery to Pancreatic Ductal Adenocarcinoma [J].
Aparicio-Lopez, Cesar B. ;
Timmerman, Sarah ;
Lorino, Gabriella ;
Rogers, Tatiana ;
Pyle, Marla ;
Shrestha, Tej B. ;
Basel, Matthew T. .
CANCERS, 2024, 16 (17)
[24]   The hENT1 Immunohistochemistry Diagnostic Test is Predictive of Gemcitabine Outcome in Pancreatic Ductal Adenocarcinoma [J].
Raponi, Mitch ;
Isaacson, Jeff ;
Hahn, Hejin ;
Bartosiewicz, Mike ;
Magnusson, Andrea ;
Lin, Kevin ;
Rolfe, Lindsey ;
Allen, Andrew ;
Picozzi, Vincent .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 :S84-S85
[25]   THE HENT1 IMMUNOHISTOCHEMISTRY DIAGNOSTIC TEST IS PREDICTIVE OF GEMCITABINE OUTCOME IN PANCREATIC DUCTAL ADENOCARCINOMA [J].
Raponi, M. ;
Isaacson, J. ;
Hahn, H. ;
Bartosiewicz, M. ;
Magnusson, A. ;
Lin, K. ;
Rolfe, L. ;
Allen, A. ;
Picozzi, V. .
ANNALS OF ONCOLOGY, 2012, 23 :236-236
[26]   dCK expression and gene polymorphism with gemcitabine chemo-sensitivity in patients with pancreatic ductal adenocarcinoma [J].
Altaf, K. ;
Xiong, J. ;
Ke, N. ;
Wang, Y. ;
Liu, X. .
BRITISH JOURNAL OF SURGERY, 2016, 103 :36-37
[27]   Extracellular Vesicles Inhibit the Response of Pancreatic Ductal Adenocarcinoma Cells to Gemcitabine and TRAIL Treatment [J].
Rimmer, Ella ;
Rashid, Sadaf ;
Kraev, Igor ;
Miralles, Francesc ;
Elia, Androulla .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (14)
[28]   Treatment of pancreatic ductal adenocarcinoma (PDAC) by argyrin F (AF) plus gemcitabine (G) [J].
Plentz, Ruben R. ;
Chen, Xi ;
Barat, Samarpita ;
Bozko, Przemyslaw ;
Bui, Cuong ;
Sipos, Bence ;
Kalesse, Markus ;
Malek, Nisar P. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[29]   Development and Validation of the Predictive and Prognostic ChemoResist Signature in Resected Pancreatic Ductal Adenocarcinoma: Multicohort Study [J].
Huang, Lei ;
Han, Quanli ;
Zhao, Liangchao ;
Wang, Zhikuan ;
Dai, Guanghai ;
Shi, Yan .
ANNALS OF SURGERY, 2025, 281 (04) :632-644
[30]   A microRNA meta-signature for pancreatic ductal adenocarcinoma [J].
Frampton, Adam E. ;
Giovannetti, Elisa ;
Jamieson, Nigel B. ;
Krell, Jonathan ;
Gall, Tamara M. H. ;
Stebbing, Justin ;
Jiao, Long R. ;
Castellano, Leandro .
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2014, 14 (03) :267-271
12345